Soma Pharmacy Blognews

EASD: Lidocaine Patch Bests Pregabalin for Diabetic Nerve Pain (CME/CE)
VIENNA (MedPage Today) — A dermal patch containing 5% lidocaine (Lidoderm) proved as effective as pregabalin (Lyrica) in relieving neuropathic pain in diabetic patients with dramatically fewer side effects.

Vitamin D May Help Prevent Falls
Taking vitamin D supplements, at a dose of 700-1000 international units per day, may make falling 19% less likely for people age 65 and older.

Alcoholism May Alter Sleep Long-Term
Despite quitting drinking, alcoholics still have differences in their sleep than other people, a new study shows.

Study: ER Patients Wait Too Long for Care
Even the sickest patients treated in hospital emergency departments across the U.S. routinely wait longer than they should for medical care, new research suggests.

100 Worst Cities for Fall Allergies
McAllen, Texas, is the worst city in the U.S. this year for fall allergies, according to the new list of “fall allergy capitals” selected by the Asthma and Allergy Foundation of America.

Bristol-Myers Squibb, AstraZeneca Report Results For Phase 3 Dapagliflozin Study
Demonstrated improved glycemic control, and weight reduction in Type 2 Diabetes

Sanofi Pasteur Reported Results Of US Clinical Trials For Influenza A (H1N1) Vaccine
Study was conducted to test the immunogenicity and safety of Monovalent Vaccine

New study underscores lack of appropriate government action to ensure safety of vaccines
A new study in the leading scientific journal NeuroToxicology lends further credence to parents and scientists concerned about an increasingly aggressive childhood vaccine schedule and toxic vaccine components.

Array BioPharma to present poster on ARRY-403 glucokinase activator
Array BioPharma Inc. today announced that a poster on ARRY-403, a novel, oral, glucokinase activator (GKA), will be presented at the European Association for the Study of Diabetes annual meeting, on October 2, 2009, in Vienna, Austria.

Molecular mechanisms of BN108 and timosaponin AIII described in a journal
Bionovo, Inc. today announced the publication in the peer-reviewed, open-access journal Public Library of Science One (PLoS ONE) of a paper describing the molecular mechanisms underlying the selective cytotoxic activity of its drug candidate BN108 and its active compound, timosaponin AIII.